The tellurium redox immunomodulating compound AS101 inhibits IL-1β-activated inflammation in the human retinal pigment epithelium

British Journal of Ophthalmology

Volumn 97, Issue 7, 2013, Pages 934-938

  Ling, Diamond ^a   Liu, Baoying ^a   Jawad, Shayma ^a   Thompson, Ian A ^a   Nagineni, Chandrasekharam N ^a   Dailey, Jennifer ^a   Chien, Jason ^a   Sredni, Benjamin ^b   Nussenblatt, Robert B ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; TRANSCRIPTION FACTOR RELA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

IMMUNOLOGY; INFLAMMATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANGIOGENESIS INHIBITORS; BLOTTING, WESTERN; CELL COUNT; CELL LINE, TRANSFORMED; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHYLENES; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; NF-KAPPA B; OXIDATION-REDUCTION; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL PIGMENT EPITHELIUM; RNA, MESSENGER; TISSUE DONORS;

EID: 84879411633     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-301962     Document Type: Article

References (25)

1. Nussenblatt RB, Liu B, Li Z. Age-related macular degeneration: an immunologically driven disease. Curr Opin Investig Drugs 2009;10:434-42.
2. Whitcup SM, Nussenblatt RB. Immunologic mechanisms of uveitis. New targets for immunomodulation. Arch Ophthalmol 1997;115:520-5.
3. Detrick B, Hooks JJ. Immune regulation in the retina. Immunol Res 47:153-61.
4. Leung KW, Barnstable CJ, Tombran-Tink J. Bacterial endotoxin activates retinal pigment epithelial cells and induces their degeneration through il-6 and il-8 autocrine signaling. Mol Immunol 2009;46:1374-86.
5. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3:879-89.
6. Franks WA, Limb GA, Stanford MR, et al. Cytokines in human intraocular inflammation. Curr Eye Res 1992;11(Suppl):187-91.
7. Elner VM, Scales W, Elner SG, et al. Interleukin-6 (il-6) gene expression and secretion by cytokine-stimulated human retinal pigment epithelial cells. Exp Eye Res 1992;54:361-8.
8. Elner SG, Elner VM, Bian ZM, et al. Human retinal pigment epithelial cell interleukin-8 and monocyte chemotactic protein-1 modulation by t-lymphocyte products. Invest Ophthalmol Vis Sci 1997;38:446-55.
9. Kinnunen K, Petrovski G, Moe MC, et al. Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol 2012;90:299-309.
10. Caspi R. Autoimmunity in the immune privileged eye: pathogenic and regulatory t cells. Immunol Res 2008;42:41-50.
11. Liu B, Wei L, Meyerle C, et al. Complement component c5a promotes expression of il-22 and il-17 from human t cells and its implication in age-related macular degeneration. J Transl Med 2011; 9:1-12.
12. Sredni B, Caspi RR, Klein A, et al. A new immunomodulating compound (as-101) with potential therapeutic application. Nature 1987;330:173-6.
13. Blank M, Sredni B, Albeck M, et al. The effect of the immunomodulator agent as101 on interleukin-2 production in systemic lupus erythematosus (sle) induced in mice by a pathogenic anti-DNA antibody. Clin Exp Immunol 1990;79:443-7.
14. Sredni B. Immunomodulating tellurium compounds as anti-cancer agents. Semin Cancer Biol 2012;22:60-9.
15. Okun E, Arumugam TV, Tang SC, et al. The organotellurium compound ammonium trichloro(dioxoethylene-0,00) tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice. J Neurochem 2007;102:1232-41.
16. Brodsky M, Hirsh S, Albeck M, et al. Resolution of inflammation-related apoptotic processes by the synthetic tellurium compound, as101 following liver injury. J Hepatol 2009;51:491-503.
17. Brodsky M, Yosef S, Galit R, et al. The synthetic tellurium compound, as101, is a novel inhibitor of il-1beta converting enzyme. J Interferon Cytokine Res 2007;27:453-62.
18. Brodsky M, Halpert G, Albeck M, et al. The anti-inflammatory effects of the tellurium redox modulating compound, as101, are associated with regulation of NFkappaB signaling pathway and nitric oxide induction in macrophages. J Inflamm (Lond) 2010;7:3.
19. Nagineni CN, Detrick B, Hooks JJ. Synergistic effects of gamma interferon on inflammatory mediators that induce interleukin-6 gene expression and secretion by human retinal pigment epithelial cells. Clin Diagn Lab Immunol 1994;1:569-77.
20. Vermeulen L, De Wilde G, Notebaert S, et al. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol 2002;64:963-70.
21. Tak PP, Firestein GS. Nf-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
22. La Flamme AC, Pearce EJ. The absence of il-6 does not affect th2 cell development in vivo, but does lead to impaired proliferation, il-2 receptor expression, and b cell responses. J Immunol 1999;162:5829-37.
23. Ghasemi H, Ghazanfari T, Yaraee R, et al. Roles of il-8 in ocular inflammations: a review. Ocul Immunol Inflamm 19:401-12.
24. Chi W, Zhu X, Yang P, et al. Upregulated il-23 and il-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci 2008;49:3058-64.
25. Dastgheib K, Hikita N, Sredni B, et al. Ocular inflammation stimulated by the immunomodulator as101 [ammonium trichloro(dioxyethelene-o-o0) tellurate]. Curr Eye Res 1994;13:603-10.